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Abstract
Motivation: Recent breakthroughs in cancer research have come via the up-and-coming field of
pathway analysis. By applying statistical methods to prior known gene and protein regulatory informa-
tion, pathway analysis provides a meaningful way to interpret genomic data. While many gene/protein
regulatory relationships have been studied, never before has such a significant amount data been made
available in organized forms of gene/protein regulatory networks and pathways. However, pathway anal-
ysis research is still in its infancy, especially when applying it to solve practical problems.
Results: In this paper we propose a new method of studying biological pathways, one that cross ana-
lyzes mutation information, transcriptome and proteomics data. Using this outcome, we identify routes
of aberrant pathways potentially responsible for the etiology of disease. Each pathway route is encoded
as a bayesian network which is initialized with a sequence of conditional probabilities specifically de-
signed to encode directionality of regulatory relationships encoded in the pathways. Far more complex
interactions, such as phosphorylation and methylation, among others, in the pathways can be modeled
using this approach. The effectiveness of our model is demonstrated through its ability to distinguish
real pathways from decoys on TCGA mRNA-seq, mutation, Copy Number Variation and phosphory-
lation data for both Breast cancer and Ovarian cancer study. The majority of pathways distinguished
can be confirmed by biological literature. Moreover, the proportion of correctly indentified pathways
is % higher than previous work where only mRNA-seq mutation data is incorporated for breast cancer
patients. Consequently, such an in-depth pathway analysis incorporating more diverse data can give rise
to the accuracy of perturbed pathway detection.
Contact: yue.2.zhao@uconn.edu
1 Introduction
Pathway analysis has been playing an important role in cancer research. By and large, pathway anal-
ysis helps interpret genomics data by applying computational methods which combine prior known
gene/protein regulatory information. There exists ample gene/protein regulatory relationships sum-
marized in the literature that is organized into various forms of gene/protein regulatory networks and
pathways. However, pathway analysis research is still a nascent area, particularly when it comes to prac-
tical problems. For instance, breast cancer patients with the ERBB2 amplification are normally cured by
Trastuzumab. According to [Vogel et al.(2001)Vogel, Cobleigh, Tripathy, Gutheil, Harris, Fehrenbacher,
Slamon, Murphy, Novotny, Burchmore, et al.], less than fifty percent of the patients get the benefit of
the ERBB2 targeting antibody, indicating a deeper understanding of a patient’s pathway behavior is
required. Therefore, developing a more comprehensive way to analyze pathways by combining multiple
genomic data sets, which are now readily available through various high-throughput sequencing technolo-
gies (e.g., RNA-Seq, DNA-Seq, ChIP-Seq), is of great signficance. [Zhao et al.(2016)Zhao, Hoang, Joshi,
Hong, and Shin] propose an approach by modeling the pathway route as an analysis unit. Nevertheless,
this approach has many defects:
• missing values are not penalized
• more data types like Copy Number Variation (CNV) and DNA methylation data are not included
in the model
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• specific types of regulation information are not considered, such as phosphorylation, methylation
The goal of this paper is to extend that pathway analysis framework giving it the ability to include
proteomics and CNV data and the specific types of regulation mentioned above. Together with existing
transcriptome and mutation data, we aim to pinpoint the precise pathway routes perturbed. This
analysis will focus on explaining the biological mechanisms behind cancer development more accurately.
The rest of the paper is outlined as follows. In section II, existing pathway analysis methods are briefly
reviewed. Section III covers the model settings and assumptions described in detail. Section IV presents a
significance study similar to that of [Vaske et al.(2010)Vaske, Benz, Sanborn, Earl, Szeto, Zhu, Haussler,
and Stuart] using TCGA Breast Cancer data. In section V, we show the route analysis outcome of
applying our model to the data. Finally we conclude with section VI.
2 Related Work
Great efforts have been made to incorporate pathway information into genomic data analysis. One of
the first popular methods of analyzing genome-wide experimental data is using gene set enrichment
analysis methods [Subramanian et al.(2005)Subramanian, Tamayo, Mootha, Mukherjee, Ebert, Gillette,
Paulovich, Pomeroy, Golub, Lander, et al.]. [Li and Li(2008)Li and Li] encoded the pathway network
into a penalty function and did model selection by optimizing the function to pick meaningful genes
and subnetworks. [Tarca et al.(2009)Tarca, Draghici, Khatri, Hassan, Mittal, Kim, Kim, Kusanovic,
and Romero] proposed SPIA which measures pathway significance by statistical testing against random
permutation. [Vaske et al.(2010)Vaske, Benz, Sanborn, Earl, Szeto, Zhu, Haussler, and Stuart] presented
PARADIGM, a novel method by modeling the pathway as a factor graph to do patient specific infer-
ence. [Verbeke et al.(2015)Verbeke, Van den Eynden, Fierro, Demeester, Fostier, and Marchal] ranked
the pathways by p-value obtained from encoding pathway logic into a global network. The p-value is cal-
culated based on a hypothesis test where the null hypothesis is that the pathway is picked randomly. [Ko-
rucuoglu et al.(2014)Korucuoglu, Isci, Ozgur, and Otu] and [Isci et al.(2011)Isci, Ozturk, Jones, and Otu]
encode the pathway as a Bayesian network. After removing cycles in the graph, they train the model with
expression data. Significance of the score is given by bootstrap-generated data. [Zhao et al.(2016)Zhao,
Hoang, Joshi, Hong, and Shin] dynamically encode pathway routes as a Bayesian network incorporating
expression and mutation data to do the pathway analysis.
3 Methods
3.1 Model and Terms
Figure 1 illustrates the pipeline of this approach. Figure 1.A shows an example pathway, ErbB, which
has been adapted from the KEGG pathway database [Kanehisa and Goto(2000)Kanehisa and Goto]. The
pathway is then simplified to be a gene regulation network GB . Unlike most existing approaches who
merely keep activation and inhibition interactions after the simplification, different tags on the interac-
tions in the KEGG pathway are furthermore kept in GB , i.e. Phosphorylation (+p), Ubiquitination(+u),
Glycosylation(+g), Methylation(+m), Dephosphorylation(-p), Debiquitination(-u), Deglycosylation(-g),
Demethylation(-m), Expression(+e), Repression(-e). These tags are defined as evidence tags determining
the data associated with the interactions.
Among all these types of tags, Phosphorylation, Glycosylation, Methylation, Ubiquitination, Dephos-
phorylation, Deubiquitination, Deglycosylation, Demethylation do not affect the expression level of the
target gene, however, it can affect the protein product structure and function. We call all these types of
edges (Protein) Functional Interactions. For Expression and Repression edges, only expression level
of gi is affected rather than the protein function. Thus, we categorize these two type of interactions as
Expression Interactions. These two categories will be handled in distinct ways in the model.
The next step is to identify all possible “routes” available from the given G∗. Figure 1.C shows a
route which starts from ERBB2 and ends at BAD. The selected route is then converted into a discrete
Bayesian Network ( denoted as G shown by Figure 1.D). Our objective is to treat each “route” as a unit
of pathway analysis. This route-based method is more amenable as it could show whether the effect
of ERBB2 amplification is more prominent through ERBB2→SHC2 path or ERBB2→PIK3R5 path, or
even for both. The route-based modeling idea assumes that it is crucial to identify which portion(s) of
the pathway is(are) either abnormally activated or suppressed. In this way, a more informed treatment
plan could be designed.
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Figure 1: Conversion Pipeline. Part of the ErbB pathway in KEGG shown in part A. The pathway is
simplified by keeping only specific interactions and genes, resulting in gene regulation network GB in Part
B. A route G∗ shown in part C, starting from ERBB2 to BAD, is extracted from GB and converted to
a Bayesian Network G in part D. Since ERBB2 is Activating (one of Functional Interactions) PIK3R5 in
G∗, thus the nodes for ERBB2, R1 and M1 is pointing to RM2, the RM node for PIK3R5. On the other
hand, once getting activated, PIK3R5’s protein will binds to AKT3 and make it express. Thus all nodes
for PIK3R5 points to R node of AKT3, namely, R3. Distinct node colors represent different data source
(denoted as cylinders) used to calculate the observations. For instance, all R node observation comes from
mRNA-seq database for the same patient.
We then continue to illustrate the conversion process from a pathway route G∗ to a Bayesian network
G. As shonw in Fig.3, for a gene regulation network GB (converted from a pathway), a path G
∗ is simply
a subgraph of GB , G
∗ ⊆ GB , G∗ = (V ∗, E∗) where V ∗ = {g1, . . . , gkG∗ }, where gi represents the ith
gene and kG∗ is the number of genes contained in path G
∗, E∗ = {eij |1 ≤ i < kG∗ and j = i+ 1}.
For each edge in G∗, ei−1,i, 1 < i ≤ kG∗ , if i < kG∗ and ei−1,i is one of the Functional Interactions in
G∗, then we create three nodes in the corresponding Bayesian Network G : Ri, Mi and RMi for gi. On
the other hand, if i < kG∗ and ei−1,i is one of the Expression Interactions, only two nodes Ri and Mi will
be created. The first gene, g1 will always have two nodes created R1 and M1 while gkG∗ will only have
one node, either RkG∗ (if ekG∗−1,kG∗ is Expression Interaction) or RMkG∗ (if ekG∗−1,kG∗ is Functional
Interaction). In this way, there will usually be three nodes for target gene of Functional interactions and
two nodes for that of Expression interactions.
After creating nodes for each gene in the path G∗, the edges in the Bayesian network G will be added
dynamically according to the edges in pathway route G∗. For gi ∈ V ∗, 1 < i ≤ kG∗ , if ei−1,i ∈ E∗ is
one of the Functional Interactions, edges will be created pointing from all the nodes for parent gene gi−1
to the RM node child gene gi. Namely, we will add edges from Ri−1,Mi−1, (RMi−1), to RMi. On the
other hand if ei−1,i is an Expression Interaction, edges from the nodes of gi−1 (Ri−1,Mi−1, (RMi−1))
to Ri will be created instead. The conditional probability table corresponding to edges in Bayesian
Network G is determined by the type of the edge in G∗ as shown in details from Table 1 to Table 4.
The assumption is that, given the edge ei−1,i, the expression level (Ri) (or functional status RMi), of
the gene gi is affected by its parent’s expression status Ri−1, the DNA functional status Mi−1 (and the
Protein functional status RMi−1 if exists). After conversion, the resulting Bayesian Network G is formally
defined as follows: G = (V,E), where V = RR
⋃
MM
⋃
RMS, RR = {Ri, i ∈ {1, . . . , kG∗}} where Ri
is a random variable representing expression level status on gene gi. MM = {Mi, i ∈ {1, . . . , kG∗ − 1}}
where Mi is a random variable representing DNA functional status on gene gi. RMS = {RMi, i ∈ {j :
ej−1,j is one of Functional Interactions in G∗}} where RMi is a random variable representing protein
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Figure 2: Central Dogma of Molecular Biology for gene gi. Random variable Mis will be handling the DNA
functional status. Mutation and Copy Number Variation data will be used to get the observation for the M
random variable. Random variable Ri will be representing the expression status, namely, whether the mRNA
or protein of gi will be high enough be achieve the biological function. The last type of random variable RMi
stands for the functional status of the protein, for example, whether the protein has been phosphorylated
or methylated by gi’s parent gene. Only when all three parts work properly, could the interaction ei+1,i+2
take effect.
functional status on gene gi. This setting is motivated from central dogma shown in Figure 2.
Mi, Ri and RMi are now defined in detail. Since the DNA information is not affected by any
interactions in the pathway route and Mi doesn’t have a parent node in G, the random variable Mi
follows a Bernoulli distribution as shown in (1). The Bernouli random variable Mi has two possible
values: +1 represents that gi functions normally on DNA level, and −1 represents function loss, i.e. gi’s
DNA original biological function is disrupted. The probability distribution indicates the prior has no
specific preference on these two levels:
Mi =
{
+1 p = 0.5
−1 p = 0.5 (1)
Random variable Ri follows a different probability distribution based on the location of gene gi in path
G∗: Suppose gi is the starting node in G∗, Ri’s distribution is shown in (2)
Ri =

+1 p = 1/3
0 p = 1/3
−1 p = 1/3
(2)
where +1 represents gene gi is not down regulated in expression level, −1 represents gene gi is down
regulated in test cases and Ri = 0 otherwise. For cancer research, test case is equivalent to the tumor
cell. On the other hand, if gi (i > 1) has a parent, gene gi−1 in G∗, Ri will follow the conditional
probability table in Table 1(Table 2) if ei−1,i is expression(repression) in G∗. In order to illustrate our
model more clearly, we define the following operator &, which is really similar to the AND operator,
in (3). For instance, (RMi−1&)Mi−1&Ri−1 has value of +1 if none of the three (or two if there is no
4
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Figure 3: Converting the route in the pathway to Bayesian Network. The pathway route G∗ on the left is
converted to Bayesian Network G on the right. Especially, for Genej activating Genej+1, the RMj+1 has
an extra parent RMj . This illustrates the special case when Genej−1 is activating or inhibiting Genej .
RMi−1) variables are −1. Otherwise, it has value of −1.
A1&A2&, . . . , An−1&An =
{
−1 ∃i ∈ [1, n] s.t. Ai = −1
+1 otherwise
(3)
Next we show the biological logic behind the conditional probability table for Ri. Here we focus on
the expression table (Table.1); the repression table (Table.2) is built in a similar way. If the parent gene
of gi, gi−1, has no function loss in DNA, over-expresses and the functional status of gi−1’s protein is fully
activated, namely Mi−1&Ri−1&RMi−1 = +1, then the target gi will also be highly likely to overexpress,
i.e. Ri = +1, given the edge between them in G
∗ is ‘expression’. If there is no Functional Interaction
ei−2,i−1 targeting at gi−1, there will be just Ri−1 and Mi−1 in the conditional table. As a result,
P (Ri = +1|Mi−1&Ri−1&RMi−1 = +1) = 1− 1 − 2
while
P (Ri = −1|Mi−1&Ri−1&RMi−1 = +1) = 1
P (Ri = 0|Mi−1&Ri−1&RMi−1 = +1) = 2
where 1 and 2 are respectively the probability of observing Ri = −1 and Ri = 0. 1− 1 − 2 should be
close to 1. Here 1 < 2 indicating that we penalize the inconsistency more than the uncertainty. Similarly,
if the parent gene of gi has DNA function loss, caused by mutation for instance, or its expression level is
down regulated in test case, or the protein of gi−1 is not activated successfully (Mi−1&Ri−1&RMi−1 =
−1), then the downstream regulation process towards gi is likely not to be functioning. Therefore, gi
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Table 1: THE REGULATION PROCESS ei−1,i IN G∗ IS EXPRESSION
(RMi−1&)Mi−1&Ri−1 Ri = +1 Ri = 0 Ri = −1
+1 1− 1 − 2 2 1
−1 1 2 1− 1 − 2
*0 < 1 < 2 << 1− 1 − 2
Table 2: THE REGULATION PROCESS ei−1,i IN G∗ IS REPRESSION
(RMi−1&)Mi−1&Ri−1 Ri = +1 Ri = 0 Ri = −1
+1 1 2 1− 1 − 2
−1 1− 1 − 2 2 1
Table 3: THE REGULATION PROCESS ei−1,i IN G∗ IS FUNCTIONAL ACTIVATION
(RMi−1&)Mi−1&Ri−1 RMi = +1 RMi = 0 RMi = −1
+1 1− 1 − 2 2 1
−1 1 2 1− 1 − 2
Table 4: THE REGULATION PROCESS ei−1,i IN G∗ IS FUNCTIONAL INHIBITION
(RMi−1&)Mi−1&Ri−1 RMi = +1 RMi = 0 RMi = −1
+1 1 2 1− 1 − 2
−1 1− 1 − 2 2 1
would tend to be down regulated, namely Ri = −1, and hence the corresponding probability would be
flipped.
Similar to Ri, Random variable RMi has three possible values: {+1, 0,−1}, where +1 represents gene
gi has its protein switched on by its parent gene gi−1 through ei−1,i, −1 represents gene gi is switched off
and otherwise Ri = 0. Recall that RMi will be attached only when interaction ei−1,i in G∗ is Functional
Interaction, gi will always have a parent, gene gi−1 in G∗. RMi will follow the conditional probability
table from Table 3 to Table 4.
The biological logic behind the conditional probability table for RMi is built based on central dogma,
as shown in Figure 2. Here we focus on the positive effect table (Table.3); the negative effect table
(Table.4) is built in a similar way. If the parent gene of gi, gi−1, has no function loss in DNA, it
over-expresses and gi−1’s protein is successfully regulated (if RMi−1 exists) (Mi−1&Ri−1&RMi−1 =
+1), then interaction ei−1,i will take effect, thus the target gi protein will also be highly likely to be
regulated successfully, namely, Ri = +1 given the edge between them in G
∗ is one the Positive Functional
Interactions: Phosphorylation, Glycosylation, Methylation, Ubiquitination, Activation . As a result,
P (RMi = +1|Mi−1&Ri−1&RMi−1 = +1) = 1− 1 − 2
while
P (RMi = −1|Mi−1&Ri−1&RMi−1 = +1) = 1
P (RMi = 0|Mi−1&Ri−1&RMi−1 = +1) = 2
where 1 and 2 are respectively the probability of observing Ri = −1 and Ri = 0. Similarly, if the
parent gene of gi has DNA function loss, caused by mutation for instance, or its expression level is down
regulated, or the protein of gi−1 is not regulated successfully (Mi−1&Ri−1&RMi−1 = −1), then the
downstream regulation process towards gi is likely not to be functioning. Therefore, gi would tend to be
not regulated properly, namely Ri = −1, and hence the corresponding probability would be flipped.
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3.2 Ranking the Route
3.2.1 A Score Based on Conditional Probability
Given (~r, ~m, ~rm), a set of data observations of the random variables in Bayesian Network G from a
specific patient s, we could rank the path G∗ with the probability of observing ~r, ~m and ~rm conditioning
on the Bayesian network model G, P (~R = ~r, ~M = ~m, ~RM = ~rm|G). The larger the probability, the
more likely the pathway route is perturbed since the observation is highly consistent with the biological
logic from G∗ encoded in G. One problem of using this probability as a measure, is that the probability
will be higher if fewer data are observed. Thus the score displayed in (4) given in [Koller and Fried-
man(2009)Koller and Friedman], will be used instead, where the conditional probability is normalized
by P (~R, ~M, ~RM are consistent|G).
Scores(G
∗, ~r, ~m, ~rm) =
P (~R = ~r, ~M = ~m, ~RM = ~rm | G)
P (~R, ~M, ~RM are consistent | G) (4)
P (~R = ~r, ~M = ~m, ~RM = ~rm | G)
=
∑
~R=~r, ~M=~m, ~RM= ~rm
P (~R, ~M, ~RM)
=
∑
~R=~r, ~M=~m, ~RM= ~rm
∏
PaG(Ri)=∅
P (Ri)
∏
1≤i<kG∗
P (Mi)
∏
PaG(Ri)6=∅
P (Ri | PaG(Ri))
∏
PaG(RMi) 6=∅
P (RMi | PaG(RMi))
where PaG(X) is the set of containing parent nodes of nodeX in Bayesian NetworkG. P (~R, ~M, ~RM are consistent|G)
is the probability that the random variables with observations are fully consistent with the biological
logic encoded in the pathway route given R1 = +1,M1 = +1. For instance, suppose the pathway route
only contains two genes and g1 phosphorylates g2, namely, G
∗ : g1
+p−→ g2. Then we have (5):
P (~R, ~M, ~RM are consistent | G)
= P (R1 = +1,M1 = +1, RM2 = +1 | G)
(5)
(since g2 is the last node in the route and the interaction e12 is phosphorylation, then R2 and M2 are
not included in the model).
A high score means that the path G∗ is highly likely to be perturbed based on the data we observe.
A path G∗ could only get a high score if the observations, the changes in tumor cells for each gene, are
highly consistent with pathway information contained in the Bayesian Network G. Inconsistency between
data and the model would lower the score greatly since the conditional probability will be 1 instead of
1− 1 − 2 during the calculation of the score. Advantages of this measure are
• the analysis could be done across pathways, i.e. after merging pathways in a reasonable way, this
measure could recognize a significantly meaningful route across different pathways. This could allow
biologists, oncologist or doctors to see what biological processes are likely to be “making trouble”
in the patient’s body.
• even though some observation values are flipped due to random errors from the genomic data (it is
observed to be −1 when it actually +1), the whole path would still have a high score if the other
genes have consistent observations.
The data here comes from one patient, s, indicating that the score is specifically tailored to patient s.
The perturbed route could have two possible statuses, enhanced or suppressed, as we have defined
in [Zhao et al.(2016)Zhao, Hoang, Joshi, Hong, and Shin]. Recall that we define a pathway route G∗ to
be enhanced if the last gene’s expression value is observed to be the same as the expected value. The
expected value is calculated based on biological logic in G∗ by supposing R1 = +1,M1 = +1. The route
is defined to be suppressed if the observation of the last node is opposite to the expectation. The score
is easily extended to include this information, resulting in a new signed score, sScore, as shown in (6).
sScores(G
∗, ~r, ~m) = I˜(o|G∗|, o˙|G∗|) · Scores(G∗, ~r, ~m, ~rm) (6)
where oG∗ is the observation of the last gene in the route G
∗. If e|G∗|−1,|G∗| is an Expression Interaction,
then o|G∗| = r|G∗|. Otherwise, o|G∗| = rm|G∗| since e|G∗|−1,|G∗| is Functional interaction. r˙|G∗| is the
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Figure 4: Data Intergration illustration. A sample Bayesian network is shown above. All the nodes with
same color will have the same data resource. RM2 has observation extracted from phosphorylation database
because e12 is Phosphorylation or Dephosphorylation interaction in its corresponding pathway route G
∗.
Similarly, ei,i+1 is Methylation or Demethylation and ei,i+1 is Ubiquitination or Deubiquitination.
expected observation of the last gene in the route conditioning on R1 = +1,M1 = +1. Similarly, If
e|G∗|−1,|G∗| is expression interaction, then o˙|G∗| = r|G∗|. Otherwise, o˙|G∗| = rm|G∗| since e|G∗|−1,|G∗| is
Functional interaction. Function I˜ : R2 → R is defined in (7). The signed score varies from −1 (highly
suppressed) to +1 (highly enhanced).
I˜(x, y) =
{
+1 x = y
−1 x 6= y (7)
Finally we propose the measure for a whole pathway based on the route score. The pathway score for
pathway GB based on data from a group of subjects S, pScoreS(GB), is displayed in (8):
pScoreS(GB) =
1
|GB |∑
G∗∈GB
I(
1
|S|
∑
s∈S
Scores(G
∗) > β)
(8)
The above equation is formulated because of following reasons. The pathway could be partitioned to be
several routes. We then simply measure the significance of this pathway, GB , using the proportion of
routes that have an average of all the patients’ scores, calculated by (4), that is larger than threshold β.
3.3 Data Integration
The observations for each variable in the Bayesian Network G will come from multiple types of data,
as shown in Figure 4. The gene expression variable Ri value can be measured by many types of gene
expression data, for instance, Microarray, mRNA-seq, Reverse phase protein array (RPPA) among others.
Here mRNA-seq is chosen. Ri’s observation ri is generated with log2 ratio of mRNA-seq FPKM using
(11). The threshold is set to be 0.5 to tolerate the random error resulting from sequence processing. If
both protein data and mRNA-seq data are available for the same gene of the same patient and these
two data have conflicting observation, then we use protein data observation to overwrite the one from
mRNA-seq data.
8
mi, the data observed for random variables Mi is the congenital functional status for gene gi. Ob-
servation mi = −1 if it can be observed from mutation or CNV data that gi’s DNA causes function
loss for the original biological process. For instance, if we observe function loss mutation from mutation
database or serious copy number loss from CNV database, then mi = −1. Otherwise, mi = +1 standing
for not observing functional deficiency in gi DNA. Mutation annotation tools will be really helpful in
finding function loss mutation.
When it comes to the observation of RMi, rmi, the data source becomes more complex. The data
source will be determined by the specific type of ei−1,i. RMj represents different information for different
interactions. The general logic is summarized by the following equation in (9).
RMi = Typei−1,i ∗ Tagi−1,i ∗RawV aluei (9)
where Typei−1,i = +1 if ei−1,i is activation (arrow) edge and Typei−1,i = −1 if ei−1,i is inhibition;
Tagi−1,i = +1 if ei−1,i has a tag sign of (+), i.e. +p,+m,+u or +g and Tagi−1,i = −1 if ei−1,i is
with a tag of −1, i.e. −p,−m,−u or −g. RawV aluei = +1 if the database shows that the gene is
Phosphorylated, Methylated, Ubiquitinated or Glycosylated and RawV aluei = −1 if the database shows
that the gene is Dephosphorylated, Demethylated, Deubiquitinated or Deglycosylated. For instance,
if the regulation process eij is inhibition taged with phosphorylation (+p) and Phosphorylation data
shows that gi is phosphorylated, RMj = −1 ∗ 1 ∗ 1 = −1 represents that gj is swithed off. If the data
shows that the gene is not phosphorylated, RMi = −1 ∗ 1 ∗ (−1) = +1 indicating gi is not switched off
successfully through phosphorylation. If ei−1,i is methylation, then the value of rmi will be determined
from methylation database. The same goes with the other possible interactions: Phosphorylation, De-
phosphorylation, Ubiquitination, Glycosylation etc. For the edges with no tags, we assume the edge is
always working and use the fomula in (10) instead. The formula indicates that given no function loss in
Mi−1 and down expression in Ri−1, ei−1,i works and determines RMi.
RMi = Typei−1,i ∗min(Mi−1, Ri−1) (10)
4 Significance Analysis
The bioinformatics field frequently uses the TCGA Breast invasive carcinoma (BRCA) data to test newly
developed analysis models. We choose the same TCGA cancer data set to validate our model. Another
cancer data set, Ovarian serous cystadenocarcinoma (OV) , is also analyzed with the same methodology
for generality. Four types of data sets: mRNA-seq, mutation, Copy Number Variation are downloaded
from https://gdac.broadinstitute.org/ for both cancer studys. Phosphorylation data are respectively
extracted from recent work [Mertins et al.(2016)Mertins, Mani, Ruggles, Gillette, Clauser, Wang, Wang,
Qiao, Cao, Petralia, et al.] and [Zhang et al.(2016a)Zhang, Liu, Zhang, Payne, Zhang, McDermott, Zhou,
Petyuk, Chen, Ray, et al.].
The mRNA-seq data is processed as follows to obtain ri, the observation for Ri. The cancer vs.
normal paired ratios of RPKM are converted to the expression observation with (11). The value for each
item is mapped to a node in pathway by official gene symbol.
ri =

+1 log2(
TumorRPKMi
NormalRPKMi
) > 0.5
−1 log2( TumorRPKMiNormalRPKMi ) < −0.5
0 otherwise
(11)
The mutation information is extracted from mutation accessor study [Center(2016a)Center] and [Cen-
ter(2016b)Center]. The mutation with a ’medium’ or ’high’ impact factor is encoded as function loss
mutation. Other mutation observations are encoded as no function loss mutation in the data. The
value for each item is mapped to a node in pathway by ncbi-protein id. Copy Number Variation (CNV)
data is imported from GISTIC2 study [Center(2016c)Center] and [Center(2016d)Center], where the copy
number variation is quantified by integers varying from −2 to +2 and negative values are considered as
copy number loss. CNV information determines the observation for M node, m, along with mutation
information as we discussed in section 3.3. The value for each item is mapped to a node in pathway by
official gene symbol.
In the end, phosphorylation data is processed. rmi(phosphorylation) = +1 if the same patient’s
phosphosite iTRAQ log2 ratio is positive for gi and otherwise rmi(phosphorylation) = −1. Missing
values are encoded as 0. The value for each item is mapped to a node in pathway by ncbi-protein id.
However, one challenge one may encounter is that values for different residues within the same protein
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Figure 5: ROC curve for BRCA Significance study. The orange, red, blue, green and purple curve corresponds
to β = 0.1, 0.2, 0.3, 0.4, 0.5 seperately. The threshold is picked from [0,1] with a step of 1/10000.
may be inconsistent, and KEGG pathway fails to provide sufficient information on the specific residue
involved for each phosphorylation. As a result, only the consistent signal is considered in the experiment.
All KEGG Homo Sapien pathways are used in this study, and the implementation is done mainly with
R package “KEGGgraph” [Zhang and Wiemann(2009)Zhang and Wiemann] and “gRain” [Højsgaard(2012)Højsgaard].
Next we do a significance analysis similar to that of PARADIGM [Vaske et al.(2010)Vaske, Benz,
Sanborn, Earl, Szeto, Zhu, Haussler, and Stuart]. We will produce decoy pathways by permuting the
genes in the pathway while keeping the interactions. We generate one decoy pathway for each of 308
KEGG pathways. For each pathway, we extract all possible routes in it. Then for each route, we
calculate the score for each pathway by (8). We go on to rank the significant real pathways and their
corresponding decoy pathway. A threshold is set to do prediction, i.e. the cases with a score higher than
the threshold is predicted to be a real pathway. After obtaining False positive rate and True positive
rate with various thresholds, the resulting ROC (Receiver operating characteristic) curve can be seen
in Figure 5 and Figure 6. The AUC gets to 0.77(0.72) when taking the threshold β = 0.52(1.00) for
BRCA(OV). Furthermore, while taking the same value of β, the top significant pathways for Breast
cancer (BRCA) and Ovarian Cancer (OV) are filtered out from the 44 signaling Homo Sapien pathways
and listed in Table 5 and Table 6. The second column corresponds to the score for the real pathway by
(8). The third column contains the score for the corresponding decoy pathway. The pathways with a
score less than its corresponding decoy pathway are filtered out.
4.1 BRCA Pathways Verification
The result for Breast cancer is firstly verified by biomedical literatures. The pathways in Table.5 is
reviewed one by one. In breast cancer Neurotrophins and their receptors significantly impact tumor cell
growth and metastasis through various signaling pathways according to [Hondermarck(2012)Hondermarck].
Vascular endothelial growth factor (VEGF) is the most prominent among the angiogenic cytokines and
is believed to play a central role in the process of neovascularization, both in cancer as well as other
inflammatory diseases [Kieran et al.(2012)Kieran, Kalluri, and Cho]. In primary breast cancer, AMPK
activity is known diminished in an estimated 90% of cases [Li et al.(2015)Li, Saud, Young, Chen, and
Hua]. Dysfunction of Hippo pathway components is linked with breast cancer stem cell regulation
and the connection between the disease and genetic variations in the pathway is reported in [Zhang
et al.(2016b)Zhang, Yao, Hu, Zhu, Liu, Lunetta, Haddad, Yang, Shen, Hong, et al.]. Activation of the
phosphoinositide 3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is commonly
reported in breast cancer [Lee et al.(2015)Lee, Loh, and Yap]. Involvement of the cAMP/protein kinase
A pathway and of mitogen-activated protein kinase in the anti-proliferative effects of anandamide in
human breast cancer cells is discussed in [Melck et al.(1999)Melck, Rueda, Galve-Roperh, De Petrocellis,
Guzma´n, and Di Marzo]. [Buck and Knabbe(2006)Buck and Knabbe] discuss the key role of TGF-β
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signaling. ErbB signaling pathway is well known frequently dysregulated in breast cancer [Yarden and
Sliwkowski(2001)Yarden and Sliwkowski]. The critical role for NF-κB signaling pathway is discussed
in [Shostak and Chariot(2011)Shostak and Chariot]. According to Wang and Li, LOX-1 is up-regulated
by TNF in endothelial cell promoting the adhesion and trans-endothelial migration of MDA-MB-231
breast cancer cells [Wang and Lin(2008)Wang and Lin]. An excellent review summarizing the role of
the toll-like receptor signaling pathway on breast cancer risk, disease progression, survival, and disease
recurrence is given in [La Creis et al.(2013)La Creis, Rogers, Yeyeodu, Jones, and Kimbro]. Oxytocin
Receptors is related to breast cancer according to [Reversi et al.(2005)Reversi, Cassoni, and Chini].
Blockade of Wnt/β-catenin signaling suppresses breast cancer metastasis [Jang et al.(2015)Jang, Kim,
Cho, Park, Jung, Lee, Hong, and Nam]. When it comes to Calcium signaling pathway, specific Ca(2+)
channels reportedly play important roles in the proliferation and invasiveness of breast cancer cells [Az-
imi et al.(2014)Azimi, Roberts-Thomson, and Monteith]. [Kasper et al.(2009)Kasper, Jaks, Fiaschi, and
Toftg˚ard] conclude that the inhibition of Hedgehog signalling in breast tumours may interfere with the
maintenance of a putative cancer stem cell compartment and the abnormal stimulation of tumour stroma.
Oestrogen is known to trigger the sphingolipid signaling cascade in various tissues including breast can-
cer [Sukocheva and Wadham(2014)Sukocheva and Wadham].
Overall, we found that 94% (17/18) of the pathways in Table 5 have some published facts implicated
in breast cancer, suggesting that our analysis is producing meaningful outcomes. The only one that is
not confirmed by literatures is marked with ∗ and deserves further investigation. Furthermore, we could
also look into the perturbed routes in each pathway reported here and it is attached in supplementary
document as Table.S1 due to its large size.
4.2 OV Pathways Verification
The ovarian cancer result is also validated in a similar way. TNF secretion by ovarian cancer cells
stimulated a constitutive network consisting of cytokines, chemokines, and angiogenic factors that pro-
moted colonization of the peritoneum and neovascularization for developing tumor deposits [Wang and
Lin(2008)Wang and Lin]. VEGF has also been implicated in the pathogenesis of ovarian cancer accord-
ing to [Moghaddam et al.(2012)Moghaddam, Amini, Morris, and Pourgholami]. For MAPK pathway,
MEK4 suppresses metastasis based on its downregulation in prostate and ovarian cancers with a high
risk of metastasis [Dhillon et al.(2007)Dhillon, Hagan, Rath, and Kolch]. [Luquain et al.(2003)Luquain,
Singh, Wang, Natarajan, and Morris] identify a novel role of phospholipase D in agonist-stimulated
lysophosphatidic acid synthesis by ovarian cancer cells. Rap1A promotes ovarian cancer metastasis via
activation of ERK/p38 and notch signaling [Lu et al.(2016)Lu, Wang, Wu, Wan, and Yang]. [Hanrahan
et al.(2012)Hanrahan, Schultz, Westfal, Sakr, Giri, Scarperi, Janikariman, Olvera, Stevens, She, et al.]
reported that ovarian cancer cell lines (23.5%) had RAS/RAF pathway aberrations. The ras-signaling
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Table 5: SIGNIFICANT PATHWAY REPORTED FOR BRCA
Pathway Real Score Decoy Score
Adipocytokine signaling pathway * 0.02 0
Neurotrophin signaling pathway 0.008281573 0
VEGF signaling pathway 0.007518797 0
AMPK signaling pathway 0.005676443 0
Hippo signaling pathway multiple species 0.004608295 0
PI3KAkt signaling pathway 0.004464286 0
cAMP signaling pathway 0.003601441 0
TGFbeta signaling pathway 0.003039514 0
ErbB signaling pathway 0.002814919 0
NFκB signaling pathway 0.002477291 0
TNF signaling pathway 0.00210084 0
Tolllike receptor signaling pathway 0.001174168 0
Oxytocin signaling pathway 0.020889488 0.000673854
Hippo signaling pathway 0.002457002 0.000117
Wnt signaling pathway 0.005074161 0.00058548
Calcium signaling pathway 0.014311736 0.00234192
Hedgehog signaling pathway 0.00487013 0.001623377
Sphingolipid signaling pathway 0.007585335 0.003792668
pathway has attracted considerable attention as a target for anticancer therapy because of its impor-
tant role in carcinogenesis [Adjei(2001)Adjei]. [Szkandera et al.(2013)Szkandera, Kiesslich, Haybaeck,
Gerger, and Pichler] highlights the crucial role of Hedgehog signaling in the development and progression
of ovarian cancer. Findings argue that the Hippo signaling pathway defines an important pathway in
progression of ovarian cancer in [Hall et al.(2010)Hall, Wang, Miao, Oliva, Shen, Wheeler, Hilsenbeck,
Orsulic, and Goode]. According to [Cheaib et al.(2015)Cheaib, Auguste, and Leary], phosphatidylinosi-
tol 3 kinase (PI3K) pathway is frequently altered in cancer, including ovarian cancer (OC). Compelling
evidence suggests that NF-κB plays a critical role in ovarian cancer in [White et al.(2011)White, Rider,
Kalli, Knutson, Jarvik, and Goode]. [Arend et al.(2013)Arend, London˜o-Joshi, Straughn, and Buchs-
baum] review the Wnt/β-catenin pathway as it relates to epithelial ovarian cancer, specifically its role in
chemoresistance and its potential role as a target for chemosensitization. Inhibition of the JAK2/STAT3
pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tu-
mor burden [Abubaker et al.(2014)Abubaker, Luwor, Zhu, McNally, Quinn, Burns, Thompson, Findlay,
and Ahmed]. The mammalian target of rapamycin (mTOR) is frequently activated in epithelial ovarian
cancer, and is regarded as an attractive therapeutic target for therapy in [Mabuchi et al.(2011)Mabuchi,
Hisamatsu, and Kimura]. [Corney et al.(2008)Corney, Flesken-Nikitin, Choi, and Nikitin] review the role
of tumor suppressor p53 and the Rb pathway in EOC with particular attention to association of p53 to
high grade serous carcinomas as opposed to low grade and benign tumors.
Overall, we found that 82% (14/17) of the pathways in Table 6 have some published facts implicated
in ovarian cancer, suggesting that our analysis is producing meaningful outcomes. Furthermore, we could
also look into the perturbed routes in each pathway reported here and it is attached in supplementary
document as Table.S2 due to its large size.
5 Discussion
We further extend the existing deep pathway analysis approach by introducing more detailed informa-
tion in the pathway. Unlike existing methods, the model has the ability to handle multiple types of data
including CNV, proteomics and methylation data. We first demonstrated the performance of the model
through significance study with real data, and compare the result against PARADIGM and SPIA. Signif-
icant pathways reported can be verifed by current literature. In the end, we carried out a pathway route
analysis (deep pathway analysis) combined with verification from biological literature. Our Bayesian
based approach can be further augmented with additional statistical and machine learning methods, for
example, for enhanced model selection, hypothesis test, parameter estimation
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Table 6: SIGNIFICANT PATHWAY REPORTED FOR OV
Pathway Real Score Decoy Score
RIGIlike receptor signaling pathway * 0.008299381 0
TNF signaling pathway 0.007509387 0
VEGF signaling pathway 0.006718925 0
MAPK signaling pathway 0.003164489 0
Phospholipase D signaling pathway 0.002879539 0
Rap1 signaling pathway 0.001560912 0
Ras signaling pathway 0.001462766 0
Hedgehog signaling pathway 0.000725338 0
Hippo signaling pathway 0.000487915 0
PI3KAkt signaling pathway 0.000434485 0
NFκB signaling pathway 0.000368958 0
Wnt signaling pathway 0.001947448 5.85E-05
JakSTAT signaling pathway 2.27E-05 0
NODlike receptor signaling pathway * 0.002733265 0.000359842
mTOR signaling pathway 0.00377488 0.000691244
p53 signaling pathway 0.001706679 0.000458365
AGERAGE signaling pathway * 0.006871944 0.001952085
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